Pinnacle Associates’s ImmunityBio IBRX Stock Holding History

Pinnacle Associates’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-107,775	Closed	-$196K	–	830
2023 Q1	$196K	Buy	+107,775	New	+$335K	﹤0.01%	728

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Pinnacle Associates's IBRX Position: Q2 2023 in Review

Pinnacle Associates sold out of ImmunityBio (IBRX) in Q2 2023, closing a stake of 107,775 shares — an estimated $196K sold.

Pinnacle Associates first reported a position in IBRX in Q1 2023 and held it in 1 quarter. The position peaked at $196K in Q1 2023. 117 funds tracked by Wall St. Rank hold IBRX as of Q2 2023.

Pinnacle Associates reported no remaining ImmunityBio position as of Q2 2023 after selling out during the quarter.
Pinnacle Associates sold 107,775 ImmunityBio shares in Q2 2023, an estimated $196K.
Pinnacle Associates first reported a position in ImmunityBio in Q1 2023 and held it in 1 quarter.
Pinnacle Associates's ImmunityBio position peaked at $196K in Q1 2023.
117 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2023.

Based on Pinnacle Associates's 13F filing for Q2 2023, filed 27 Jul 2023.